Effectiveness and safety of R-GCD (rituximab, gemcitabine, carboplatin, and dexamethasone) for transplant-ineligible relapse/refractory diffuse large B-cell lymphoma and grade 3a follicular lymphoma: a retrospective analysis comparing with R-GDP (rituximab, gemcitabine, cisplatin, and dexamethasone). Issue 6 (12th May 2022) - Naka, Ryosuke; Tada, Kohei; Kaneko, Hitomi; Nagata, Osamu; Tashima, Masaharu; Mizutani, Chisato; Imada, Kazunori